Class A Common Stock, Par Value $0.0001 Per Share
- Symbol
- BIVI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
BioVie Inc.
BIVINASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 6, 2026, BioVie Inc. (the “ Company ”) issued a press release announcing results from the Company’s Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.…
Press release in this filing
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease →Company context
We are a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
Current securities
Registered securities in this filing
BioVie Inc. · 8-K · Filed 2026-08-06
Warrants to purchase Class A Common Stock, $0.0001 par value per share
- Symbol
- BIVIW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On August 6, 2026, BioVie Inc. (the
“ Company ”) issued a press release announcing results from the Company’s Phase 2 SUNRISE-PD trial evaluating its
drug candidate bezisterim in early-stage Parkinson’s disease. A copy of the press release is attached hereto as Exhibit 99.1 and
incorporated by reference herein.
The information in this Item 7.01,
including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, and
shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.